Advert
Advert

MRes Cancer Technology

  • DeadlineStudy Details:

    MRes 1 year full-time

Course Description

Develop a unique understanding of cancer from a bioengineering perspective

This course equips you with skills to address tomorrow’s challenges in cancer using state-of-the-art technologies and physical sciences/mathematical approaches.

The course involves lectures and practical work in the first term, followed by full-time work on a research project. A variety of seminars and workshops are also provided to deepen and broaden your skill base.

The course embodies a multi-disciplinary approach that:

Provides a critical understanding of the fundamentals of cancer progression and current challenges in cancer management

Enables students to apply their knowledge of engineering, physics and mathematics to solving challenges in cancer through a nine-month cross-disciplinary research project

Develops research and analytical skills related to bioengineering in cancer and to effectively communicate results through oral and written scientific formats

Trains students to effectively communicate with oncologists, cancer biologists, clinicians and researchers

Prepare students for demanding careers or PhD programmes at the interface of cancer and bioengineering

The course builds on the Department of Bioengineering’s diverse strengths in this area in addition to our collaborations with our world-leading partner, the Institute of Cancer Research.

Entry Requirements

Our minimum requirement is normally a 2.1 degree in an engineering discipline, or physical, mathematical, medical or biological science, or equivalent.

Students with a minimum 2.1 degree in medical science, biology or cancer-related subject may be admitted if they have a demonstrated track record of training or engagement in engineering, biophysics, cancer technologies or mathematics.

Find out more

Fees

For fees and funding options, please visit website to find out more

Imperial Campus

Where is Imperial?

Videos

View Website

University Profile